MTEM Molecular Templates Inc.

13.71
-0.26  -2%
Previous Close 13.97
Open 14.07
Price To Book 11.33
Market Cap 601,437,272
Shares 43,868,510
Volume 224,724
Short Ratio
Av. Daily Volume 377,133
Stock charts supplied by TradingView

NewsSee all news

  1. Molecular Templates Provides Corporate Update and Outlines 2020 Milestones

    AUSTIN, Texas, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (NASDAQ:MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company's proprietary targeted

  2. Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors

    AUSTIN, Texas, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (NASDAQ:MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company's proprietary engineered

  3. Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting

    AUSTIN, Texas, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (NASDAQ:MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company's proprietary engineered

  4. Molecular Templates to Present at Two December Investor Conferences

    AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company's proprietary engineered

  5. Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

    AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM) (the "Company" or "Molecular"), a clinical-stage biopharmaceutical company focused on the discovery and development of the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due throughout 2020.
MT-3724 and chemotherapy
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Development discontinued due to poor data - September 29, 2016.
Tarloxotinib
Cancer - mutant EGFR-positive, T790M-negative advanced non-small cell lung cancer
Phase 3 endpoints not met
Evofosfamide MAESTRO
Cancer - Pancreatic
Phase 3 endpoints not met
Evofosfamide
Cancer - soft tissue sarcoma (406 trial)
Independent Data Safety Monitoring Board conducted unlikely to reach primary endpoint - trial closed
Evofosfamide
Cancer - second line NSCLC
Development discontinued due to poor data - September 29, 2016.
Tarloxotinib
Cancer - Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin
Phase 2 data due throughout 2020.
MT-3724 and Revlimid
Diffuse large B-cell lymphoma (DLBCL)
Phase 2 data due throughout 2020.
MT-3724
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Phase 1 interim data due 2Q 2020.
MT-5111
HER2-positive solid tumors
Phase 1 trial initiated 4Q 2019.
TAK-169

Latest News

  1. Molecular Templates Provides Corporate Update and Outlines 2020 Milestones

    AUSTIN, Texas, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (NASDAQ:MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company's proprietary targeted

  2. Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors

    AUSTIN, Texas, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (NASDAQ:MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company's proprietary engineered

  3. Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting

    AUSTIN, Texas, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (NASDAQ:MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company's proprietary engineered

  4. Molecular Templates to Present at Two December Investor Conferences

    AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company's proprietary engineered

  5. Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

    AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM) (the "Company" or "Molecular"), a clinical-stage biopharmaceutical company focused on the discovery and development of the

  6. Molecular Templates, Inc. Announces Proposed Public Equity Offering

    AUSTIN, Texas, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM) (the "Company" or "Molecular"), a clinical-stage biopharmaceutical company focused on the discovery and development of the

  7. Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

    -Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE

  8. Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111

    EDMONTON, Alberta, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrolment of the first patient in a Phase I study with

  9. Molecular Templates, Inc. Reports Third Quarter 2019 Financial Results

    AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular, " "Molecular Templates" or "MTEM")), a clinical-stage biopharmaceutical company focused on the discovery and

  10. Molecular Templates Hosting Analyst & Investor Meeting

    AUSTIN, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company's proprietary engineered

  11. Molecular Templates to Present at the Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences

    AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company's proprietary engineered